1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.55%
Cash & equivalents declining -7.55% while Drug Manufacturers - Specialty & Generic shows -6.01% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
-16.45%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-9.93%
Near the Drug Manufacturers - Specialty & Generic median of -9.93% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
8.36%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.69%. Jim Chanos might see a serious red flag in ballooning receivables.
0.65%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-1.49%
Near Drug Manufacturers - Specialty & Generic median of -1.49%. Charlie Munger sees typical short-term asset changes. Check for normal seasonal variations.
-2.55%
1.25-1.5x the Drug Manufacturers - Specialty & Generic median of -2.10%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
0.06%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -2.53%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
-0.45%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-4.64%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -2.04%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-1.76%
Near Drug Manufacturers - Specialty & Generic median of -1.76%. Charlie Munger sees standard intangible additions in line with sector M&A or IP expansions.
-5.56%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
-0.64%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-1.46%
Near the Drug Manufacturers - Specialty & Generic median of -1.46%. Charlie Munger sees a standard approach to long-term asset investment.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.69%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-2.74%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of -0.54%. Jim Chanos might see a warning sign of stressed supplier payments.
-1.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
1.84%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
No Data
No Data available this quarter, please select a different quarter.
-88.12%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -6.52%. Jim Chanos suspects a potential short-term burden spike.
-5.12%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.18%. Jim Chanos suspects potential working capital strain.
-5.67%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-82.83%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-5.21%
1.25-1.5x Drug Manufacturers - Specialty & Generic median of -3.87%. Guy Spier is cautious about bigger expansions in LT liabilities.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.63%. Jim Chanos suspects an alarming rise in overall leverage.
5.68%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.99%. Jim Chanos suspects heavier share issuance than peers.
-3.16%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.12%. Joel Greenblatt sees stronger retained profit growth vs. peers.
100.00%
AOCI growth below half of Drug Manufacturers - Specialty & Generic median -2.25%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-0.15%
Below half Drug Manufacturers - Specialty & Generic median of 3.15%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-1.65%
Below half Drug Manufacturers - Specialty & Generic median of 0.09%. Jim Chanos suspects a major slowdown or distress.
-15.42%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-3.77%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.15%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
0.47%
Below half of Drug Manufacturers - Specialty & Generic median 2.08%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
